[1]Patent:US2010/292197,2010,A1.Locationinpatent:Page/Pagecolumn14
[2]Patent:US9248088,2016,B2.Locationinpatent:Page/Pagecolumn21
[3]ChemicalandPharmaceuticalBulletin,1983,vol.31,p.698-708
[4]ChemistryofNaturalCompounds,2004,vol.40,p.40-44
[5]ChemistryofNaturalCompounds,1998,vol.34,p.672-675
[6]ChemistryofNaturalCompounds,1998,vol.34,p.672-675
[7]ChemistryofNaturalCompounds,2009,vol.45,p.595-596
[8]AdvancedSynthesisandCatalysis,2012,vol.354,p.527-539
[9]Patent:CN109942663,2019,A.Locationinpatent:Paragraph0024-0066
Title: In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator.
Journal: Drug metabolism and pharmacokinetics 20100101
Title: Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182.
Title: Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032.
Title: Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304.
